{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:50:32Z","timestamp":1791953432280,"version":"4.3.4"},"reference-count":35,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The WHO European Region has the highest rates of drug-resistant TB globally. Therefore, we studied the availability of genotypic and phenotypic drug susceptibility testing (DST), including targeted next-generation sequencing and whole genome sequencing, for first- and second-line drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHOD<\/jats:title>\n                    <jats:p>In 2024, the results of an online survey completed by national and supranational reference laboratories (or equivalent) of 53 countries, territories, and areas of the WHO European Region were reviewed. The availability of DST was analysed using three denominators: 1) the number of countries, territories, and areas for all drugs; 2) the estimated 2024 TB incidence for first-line drugs, including fluoroquinolones; and 3) the estimated 2024 rifampicin-resistant TB incidence for the remaining drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The most important gap in the availability of DST was for pretomanid, the most recently approved anti-TB drug: phenotypic DST was only available for 4% of the estimated incident cases of rifampicin-resistant TB in countries where pretomanid is approved or used programmatically. This contrasted with an availability of phenotypic DST of &gt;98% for bedaquiline, delamanid, and linezolid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The delay between the introduction of novel drugs and the availability of robust DST services should be minimised to avoid intrinsic and selected resistance to novel drugs going unnoticed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.25.0600","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:30:36Z","timestamp":1791952236000},"page":"662-669","source":"Crossref","is-referenced-by-count":0,"title":["Availability of genotypic and phenotypic drug susceptibility testing for\n                    <i>Mycobacterium tuberculosis<\/i>\n                    in WHO European Region"],"prefix":"10.5588","volume":"3","author":[{"given":"C.U.","family":"K\u00f6ser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Paspaliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Cabibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yedilbayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ehsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101321302909000_3.10.662.1","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: WHO, 2025."},{"issue":"1","key":"2026101321302909000_3.10.662.2","doi-asserted-by":"crossref","first-page":"e0296448","DOI":"10.1371\/journal.pone.0296448","article-title":"Global adoption of 6-month drug-resistant TB regimens: projected uptake by 2026","volume":"19","author":"Gupta","year":"2024","journal-title":"PLoS One"},{"key":"2026101321302909000_3.10.662.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.02.027"},{"key":"2026101321302909000_3.10.662.4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac070"},{"issue":"10","key":"2026101321302909000_3.10.662.5","doi-asserted-by":"crossref","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm","year":"2023","journal-title":"PLoS Glob Public Heal"},{"issue":"1","key":"2026101321302909000_3.10.662.6","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1038\/s41467-026-73551-w","article-title":"Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing","volume":"17","author":"Vambe","year":"2026","journal-title":"Nat Commun"},{"issue":"5","key":"2026101321302909000_3.10.662.7","doi-asserted-by":"crossref","first-page":"e01839-24","DOI":"10.1128\/aac.01839-24","article-title":"Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia","volume":"69","author":"Ardizzoni","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2026101321302909000_3.10.662.8","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC-Antimicrob Resist"},{"issue":"10","key":"2026101321302909000_3.10.662.9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S1473-3099(24)00294-9","article-title":"Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis","volume":"24","author":"Decroo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026101321302909000_3.10.662.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00639-2023"},{"issue":"3","key":"2026101321302909000_3.10.662.11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3201\/eid2703.204418","article-title":"Limited capability for testing Mycobacterium tuberculosis for susceptibility to new drugs","volume":"27","author":"Farooq","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026101321302909000_3.10.662.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.07.005"},{"key":"2026101321302909000_3.10.662.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.026"},{"issue":"9","key":"2026101321302909000_3.10.662.14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cmi.2024.06.001","article-title":"Re: \u2018availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe\u2019 by Lange et al","volume":"30","author":"Friesen","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026101321302909000_3.10.662.15","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.lanepe.2025.101380","article-title":"Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026101321302909000_3.10.662.16","unstructured":"World Health Organization . WHO MDR\/RR-TB burden estimates. https:\/\/extranet.who.int\/tme\/generateCSV.asp?ds=mdr_rr_estimates (Accessed 15 January 2026)."},{"issue":"10","key":"2026101321302909000_3.10.662.17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cmi.2024.06.028","article-title":"How to verify and validate a clinical microbiology test before it can be used in routine diagnostics: a practical guide","volume":"30","author":"Yusuf","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026101321302909000_3.10.662.18","unstructured":"World Health Organization . Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed. Geneva: WHO, 2023."},{"issue":"5","key":"2026101321302909000_3.10.662.19","doi-asserted-by":"crossref","first-page":"e01781-23","DOI":"10.1128\/spectrum.01781-23","article-title":"In vitro activity of new combinations of \u03b2-lactam and \u03b2-lactamase inhibitors against the Mycobacterium tuberculosis complex","volume":"11","author":"Lundeberg","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"5","key":"2026101321302909000_3.10.662.20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cmi.2024.12.035","article-title":"More nuance and transparency are needed when setting breakpoints for antimicrobial susceptibility testing of pretomanid","volume":"31","author":"K\u00f6ser","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026101321302909000_3.10.662.21","unstructured":"World Health Organization . WHO operational handbook on tuberculosis: module 3: diagnosis. Geneva: WHO, 2025."},{"key":"2026101321302909000_3.10.662.22","unstructured":"World Health Organization . WHO TB burden estimates. https:\/\/extranet.who.int\/tme\/generateCSV.asp?ds=estimates (Accessed 15 January 2026)."},{"key":"2026101321302909000_3.10.662.23","unstructured":"World Health Organization . Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex. Geneva: WHO, 2022."},{"key":"2026101321302909000_3.10.662.24","unstructured":"TB Alliance . Access to the BPaL regimen. https:\/\/www.tballiance.org\/access-countries\/ (Accessed 7 February 2025)."},{"key":"2026101321302909000_3.10.662.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32455-1"},{"key":"2026101321302909000_3.10.662.26","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02116-16"},{"key":"2026101321302909000_3.10.662.27","unstructured":"UK Health Security Agency . Guidance national mycobacterium reference service-south: user handbook (updated 25 August 2023). https:\/\/www.gov.uk\/government\/publications\/national-mycobacterium-reference-laboratory-nmrl-user-manual\/nmrs-south-user-handbook (Accessed 3 October 2024)."},{"issue":"17","key":"2026101321302909000_3.10.662.28","doi-asserted-by":"crossref","first-page":"2400211","DOI":"10.2807\/1560-7917.ES.2024.29.17.2400211","article-title":"Availability of drugs for the treatment of multidrug-resistant\/rifampicin-resistant tuberculosis in the World Health Organization European region, October 2023","volume":"29","author":"Otto-Knapp","year":"2024","journal-title":"Eurosurveillance"},{"key":"2026101321302909000_3.10.662.29","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: WHO, 2020."},{"issue":"10","key":"2026101321302909000_3.10.662.30","doi-asserted-by":"crossref","first-page":"e0222925","DOI":"10.1371\/journal.pone.0222925","article-title":"Introduction of quality management in a National Reference Laboratory in Germany","volume":"14","author":"Homolka","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"2026101321302909000_3.10.662.31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5588\/ijtld.21.0428","article-title":"Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB","volume":"25","author":"K\u00f6ser","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2026101321302909000_3.10.662.32","doi-asserted-by":"crossref","first-page":"e02244-22","DOI":"10.1128\/spectrum.02244-22","article-title":"Experiences from 4 years of organization of an external quality assessment for Mycobacterium tuberculosis whole-genome sequencing in the European Union\/European Economic Area","volume":"11","author":"Anthony","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026101321302909000_3.10.662.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2026.05.012"},{"key":"2026101321302909000_3.10.662.34","unstructured":"BD. Urgent: medical device correction - expansion. Type of action: product removal \u2013 discarded by customer BD BACTECTM MGITTM 960 PZA Kit. https:\/\/bdx.my.salesforce.com\/sfc\/p\/#30000000Y0Yr\/a\/Ho000001rSpM\/yL62cXsX2KyAfMfCa5GywLK9AA6qzWNmfe7U2eOUks0 (Accessed 30 May 2025)."},{"issue":"1","key":"2026101321302909000_3.10.662.35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5588\/ijtld.24.0263","article-title":"Further effort is needed to avoid irrational use after drug susceptibility testing for drug-resistant TB","volume":"29","author":"Larsson","year":"2025","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.25.0600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:30:44Z","timestamp":1791952244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.25.0600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.5588\/ijtldopen.25.0600"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0600","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}